Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05387655
Other study ID # 2022-13462
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date May 20, 2022
Est. completion date June 20, 2027

Study information

Verified date November 2023
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rationale: The effects of BCG vaccination have been only sporadically studied in the elderly, and the long-term effects of the vaccination have not been studied until now. There is evidence that BCG vaccination beneficially influences susceptibility and severity of infectious and inflammatory diseases; however, the specifics, extent and duration of these effects are not known yet. With this observational study we would like to determine the extent of these effects in the elderly. Objective: To identify any long term effects of BCG vaccination on the incidence of infectious and inflammatory diseases may have in the elderly Study design: Cohort study with a duration of 5 years Study population: Older adults who participated in two large randomized BCG vaccination trials in 2020/2021 (BCG-CORONA-OUDEREN, BCG-PRIME), who have consented to be contacted for further studies Main study parameters/endpoints: The incidence of infectious and inflammatory diseases in the placebo- vs. BCG-vaccinated individuals


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4292
Est. completion date June 20, 2027
Est. primary completion date May 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Completed participation in the BCG-CORONA-ELDERLY or BCG-PRIME study - Given consent to be approached for further studies Exclusion Criteria: - Has received a BCG vaccination after the BCG-CORONA-ELDERLY or BCG-PRIME study Inclusion Criteria from BCG-PRIME: - Age =60 years - Meeting at least one of the following criteria: 1. Having a chronic somatic disease* 2. Having undergone major surgery** 3. Planned to be discharged from the hospital or discharged from the hospital less than 6 weeks ago; a hospital admission is defined as an overnight stay. Departments of interest are those that in the opinion of the principle investigator admit mostly vulnerable elderly and include but are not limited to: cardiology, pulmonology, internal medicine, neurology. 4. Attending the thrombosis care service * Chronic somatic diseases do not include risk factors such as hypertension or obesity unless the participant receives medication targeted against the risk factor. - Major surgery is any invasive operative procedure in which a more extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major Exclusion criteria from BCG-PRIME: - Fever (>38 ºC) within the past 24 hours - Suspicion of current active viral or bacterial infection; the requirement to finish an antibiotic course upon discharge is not an exclusion criterion when the infection is controlled in the opinion of the attending physician - Vaccination with live vaccine in the past four weeks or planned vaccination with live vaccine during the next four weeks - Severely immunocompromised participants. This exclusion category comprises: 1. known infection by the human immunodeficiency virus (HIV-1); 2. neutropenic with less than 500 neutrophils/mm3; 3. solid organ transplantation; 4. bone marrow transplantation; 5. hematological malignancy; 6. chemo-, radio- or immunotherapy for solid organ malignancy in the past 6 months; 7. primary immunodeficiency; 8. severe lymphopenia with less than 400 lymphocytes/mm3; 9. treatment with any immunosuppressant drugs such as anti-cytokine therapies, and treatment with oral or intravenous steroids defined as daily doses of >10 mg/day or a cumulative dose of >700 mg prednisone or equivalent for other corticosteroids in the three months prior to enrolment, or probable use of oral or intravenous steroids in the following four weeks; 10. receiving chronic renal replacement therapy. - Known history of a positive Mantoux or active TB; prior BCG vaccination or a positive Mantoux test after BCG vaccination without confirmation of TB are NOT an exclusion criterion. - Born in a country with high incidence of TB (see supplement B) - Active participation in another research study that involves BCG administration - History of documented COVID-19 (self-reported by the participant: either confirmed by a microbiological test or with clinical diagnosis during hospitalization) - Not able to perform the study procedures as judged by the attending physician - Legally incapacitated or unwilling to provide informed consent Inclusion criteria from BCG-CORONA-ELDERLY: - Adult (= 60 years) - Written informed consent Exclusion criteria from BCG-CORONA-ELDERLY: - Fever (>38 ºC) within the past 24 hours - Suspicion of current active viral or bacterial infection - Expected vaccination during the first three months of the study period - Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid organ transplantation; d) subjects with bone marrow transplantation; e) subjects under chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any immunosuppressant drugs such as anti-cytokine therapies, and treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months, or probable use of oral or intravenous steroids in the following four weeks - Active solid or non-solid malignancy or lymphoma within the prior two years - Active participation in another research study that involves BCG administration

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
BCG
BCG vaccination
Placebo vaccine
Placebo vaccination

Locations

Country Name City State
Netherlands Radboud university medical center Nijmegen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Use of antibiotics One year after the end of participation in the BCG-CORONA-ELDERLY or BCG-PRIME study; the questions in the questionnaire are about events 'in the last year' (so from the moment of sending the questionnaire)
Other Vaccination status One year after the end of participation in the BCG-CORONA-ELDERLY or BCG-PRIME study; the questions in the questionnaire are about events 'in the last year' (so from the moment of sending the questionnaire)
Other Incidence of infectious and inflammatory diseases One year since last questionnaire (so between 1-2 years after completion of original BCG trial)
Other Incidence of infectious and inflammatory diseases One year since last questionnaire (so between 2-3 years after completion of original BCG trial)
Other Incidence of infectious and inflammatory diseases One year since last questionnaire (so between 3-4 years after completion of original BCG trial)
Other Incidence of infectious and inflammatory diseases One year since last questionnaire (so between 4-5 years after completion of original BCG trial)
Other Incidence of various non-communicable diseases One year since last questionnaire (so between 1-2 years after completion of original BCG trial)
Other Incidence of various non-communicable diseases One year since last questionnaire (so between 2-3 years after completion of original BCG trial)
Other Incidence of various non-communicable diseases One year since last questionnaire (so between 3-4 years after completion of original BCG trial)
Other Incidence of various non-communicable diseases One year since last questionnaire (so between 4-5 years after completion of original BCG trial)
Other Use of antibiotics One year since last questionnaire (so between 1-2 years after completion of original BCG trial)
Other Use of antibiotics One year since last questionnaire (so between 2-3 years after completion of original BCG trial)
Other Use of antibiotics One year since last questionnaire (so between 3-4 years after completion of original BCG trial)
Other Use of antibiotics One year since last questionnaire (so between 4-5 years after completion of original BCG trial)
Other Vaccination status One year since last questionnaire (so between 1-2 years after completion of original BCG trial)
Other Vaccination status One year since last questionnaire (so between 2-3 years after completion of original BCG trial)
Other Vaccination status One year since last questionnaire (so between 3-4 years after completion of original BCG trial)
Other Vaccination status One year since last questionnaire (so between 4-5 years after completion of original BCG trial)
Primary Incidence of infectious and inflammatory disease One year after the end of participation in the BCG-CORONA-ELDERLY or BCG-PRIME study; the questions in the questionnaire are about events 'in the last year' (so from the moment of sending the questionnaire)
Secondary Incidence of various non-communicable diseases One year after the end of participation in the BCG-CORONA-ELDERLY or BCG-PRIME study; the questions in the questionnaire are about events 'in the last year' (so from the moment of sending the questionnaire)
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure